Previous close | 14.20 |
Open | 13.97 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 13.45 - 14.41 |
52-week range | 1.48 - 14.41 |
Volume | |
Avg. volume | 19,429 |
Market cap | 608.058M |
Beta (5Y monthly) | 1.62 |
PE ratio (TTM) | 0.05 |
EPS (TTM) | 2.97 |
Earnings date | 06 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Over 100,000 individuals lost their lives from overdoses last year, the majority of which were opioid related. While opioid overdoses are the leading cause of accidental death in the United States, there is an opportunity to change this statistic. In a new public education announcement, pro football hall of famer, Emmitt Smith, speaks out about opioid emergencies and the importance of being prepared. Smith has teamed up with Emergent BioSolutions (sponsor and the makers of NARCAN® Nasal Spray) a
GAITHERSBURG, Md., July 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, August 6, 2024, at 5:00 pm eastern time to discuss the financial results for the second quarter 2024, key business updates, revenue guidance for the third quarter of 2024, as well as full year guidance. Conference Call InformationParticipants can access the conference call live via webcast. To participate via telephone, please register in advance at this link. Upon
The extension to a four-year shelf-life helps improve naloxone access as communities continue to grapple with the growing opioid epidemic; product with the extended shelf life has officially begun shipping WINNIPEG, Manitoba, July 22, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions announced the shelf-life extension for NARCAN® Nasal Spray from three years (36 months) to four years (48 months) to all newly manufactured product. The update makes NARCAN® Nasal Spray the only 4 mg, intranasal